Weekly growth hormone shot tested in thousands of kids

NCT ID NCT06037473

Recruiting now Disease control Sponsor: Beijing Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is tracking 2,600 Chinese children with growth disorders who are receiving a long-acting growth hormone injection. The goal is to see how well it works and how safe it is over the long term in real-world settings. Researchers will measure changes in height and look for factors that affect treatment success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PEGylated recombinant human growth hormone injection
What this could lead to: If successful, this could confirm a convenient once-weekly growth hormone option for children with growth disorders, improving height outcomes.
What could go wrong: This is an observational registry study, not a controlled trial, so results may be less definitive. Individual responses vary, and long-term safety data are still being collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GROWTH DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fetal growth restriction hereditary endocrine growth disease isolated congenital growth hormone deficiency isolated short stature Turner syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GROWTH DISORDERS GROWTH HORMONE TREATMENT

Contacts and locations

Locations

Department of Endocrinology, Genetics, Metabolism
RECRUITING

Beijing, Beijing Municipality, 010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.